NCT06360978View on ClinicalTrials.gov

Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions
Head and Neck Cancer
Interventions
DRUG

Docetaxel

Our patients will receive docetaxel (15 mg per meter squared) once weekly concurrently with radiotherapy.

All Listed Sponsors
lead

Assiut University

OTHER

NCT06360978 - Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer | Biotech Hunter | Biotech Hunter